

Clinical Trial Protocol

Iranian Registry of Clinical Trials

23 Feb 2026

The effect of curcumin supplementation on clinical Outcomes, and some Inflammatory Markers in Patients with Ulcerative Colitis

Protocol summary

serum hs-CRP and TNF-a; ESR; Stool frequency per day;
Frequency of rectal bleeding per day

Study aim

Determination and comparison of the effect of curcumin supplement on clinical signs and some inflammatory indices (hs-CRP and TNF-a) in patients with ulcerative colitis

Design

The present study is a clinical trial of phase 3, randomized, double blind and parallel, will be carried out on 70 patients with ulcerative colitis. Patients are randomly divided into two groups. The intervention group received 3 capsules of 500 mg curcumin daily for 60 days and the control group received 3 capsules of 500 mg placebo for 60 days. Demographic data; ESR; serum hs-CRP and TNF- α , clinical signs, physical activity, and 3-day recall recording, before and after the intervention.

Settings and conduct

The present study is a double-blind clinical trial with the aim of evaluating the effect of curcumin supplement on serum TNF-a and hs-CRP in patients with ulcerative colitis at Imam khomeini Hospital, Ahvaz. Physician, researcher, patient and data analyst is not aware of the type of the treatment.

Participants/Inclusion and exclusion criteria

The severity of the disease is mild to moderate; Patients without current diagnosis of other inflammatory and autoimmune disease; The age range is between 17-70 years; Tendency to participate in the study; The patient should not be pregnant or breastfeeding; Exclusion criteria: The patient is in the acute phase of the disease; Smoking, alcohol and drug abuse; Patients with gallstones or any disorder of the gallbladder, bladder stones.

Intervention groups

Intervention group: Curcumin supplement, 1500 milligram daily, 3 times per day, 500 milligram capsule each time, for 60 days. Karen Pharma Co. Control group: Placebo, Corn starch, 3 times per day, 500 milligram capsule each time, for 60 days. Karen Pharma Co.

Main outcome variables

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20180207038664N1**

Registration date: **2018-04-30, 1397/02/10**

Registration timing: **registered_while_recruiting**

Last update: **2018-04-30, 1397/02/10**

Update count: **0**

Registration date

2018-04-30, 1397/02/10

Registrant information

Name

Narges Sadeghi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 61 3336 1984

Email address

sadeghi.n@ajums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2018-02-19, 1396/11/30

Expected recruitment end date

2018-07-22, 1397/04/31

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

The effect of curcumin supplementation on clinical Outcomes, and some Inflammatory Markers in Patients with Ulcerative Colitis

Public title

The effect of curcumin supplementation in the treatment of patients with ulcerative colitis

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Ulcerative colitis, confirmed by histopathology The severity of the disease is mild to moderate Patients without current diagnosis of other inflammatory, autoimmune and inclusive disease(including cancer, kidney disease, rheumatoid arthritis, liver disease, AIDS, and cardiovascular disease) The age range is between 17-70 years Tendency to participate in the study No changes in the type and amount of drug in the past month The patient should not be pregnant or breastfeeding

Exclusion criteria:

The patient is in the acute phase of the disease Reluctance to continue cooperation in this research History of large gastrointestinal surgery (except appendectomy, Cholecystectomy and hemorrhoidectomy) Smoking, alcohol and drug abuse Patients with gallstones or any disorder of the gallbladder, bladder stones

Age

From **17 years** old to **70 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser

Sample size

Target sample size: **70**

Randomization (investigator's opinion)

Randomized

Randomization description

Randomization in this study will be done by simple method. The unit of randomization is individual. Using a random number table, a number is considered for each patient, respectively. To the number 0-4, box A and to the number 5-9, box B delivered by an individual except the researcher. So that the person providing the treatment is unaware.

Blinding (investigator's opinion)

Double blinded

Blinding description

The type of blindness in our study will be double-blind.

Prior to the onset of the study, the box containing the relevant capsules are coded A and B by an individual except the researcher, in order to blind the researcher about which supplement each group received. When delivering supplements to patients, some one except the researcher should locate the patient in either A or B group by random number table. In this study, the patient, physician and researcher (who collecting data, assessing the outcome and analyzing the data) should be kept blind.

Placebo

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of Ahvaz University of Medical Sciences

Street address

Vice Chancellor for Research and Technology, Ahvaz Jundishapur University of Medical Sciences, Golestan Blvd, Ahvaz

City

Ahvaz

Province

Khuzestan

Postal code

61357-15794

Approval date

2018-01-20, 1396/10/30

Ethics committee reference number

IR.AJUMS.REC.1396.895

Health conditions studied**1****Description of health condition studied**

Ulcerative colitis

ICD-10 code

K51

ICD-10 code description

Ulcerative colitis

Primary outcomes**1****Description**

Serum hs-CRP

Timepoint

The beginning of the study- The end of the study

Method of measurement

ELISA

2

Description

Serum TNF-a

Timepoint

The beginning of the study- The end of the study

Method of measurement

ELISA

3

Description

Serum ESR

Timepoint

The beginning of the study- The end of the study

Method of measurement

Westergren's Method

4

Description

Stool frequency per day

Timepoint

The beginning of the study- The end of the study

Method of measurement

Mayo Score

5

Description

Frequency of rectal bleeding per day

Timepoint

The beginning of the study- The end of the study

Method of measurement

Mayo Score

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group:Curcumin supplement, 1500 milligram daily, 3 times per day ,500 milligram capsule each time, for 60 days. Karen Pharma & Food Supplement Co.

Category

Treatment - Drugs

2

Description

Control group: Placebo, Starch and edible color, 3 times per day ,500 milligram capsule each time, for 60 days. Karen Pharma & Food Supplement Co.

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Imam Khomeini Hospital

Full name of responsible person

Narges Sadeghi

Street address

Imam Khomeini Hospital,Azadegan Ave, Ahvaz

City

Ahvaz

Province

Khuzestan

Postal code

6135815751

Phone

+98 61 3321 4578

Email

sadeghi.n@ajums.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Ahvaz University of Medical Sciences

Full name of responsible person

Mohammad Badavi

Street address

Vice Chancellor for Research and Technology,Ahvaz Jundishapur University of Medical Sciences, Golestan Blvd, Ahvaz

City

Ahvaz

Province

Khuzestan

Postal code

61357-15794

Phone

+98 61 3336 7570

Fax

+98 61 3336 1544

Email

badavi-m@ajums.ac.ir

Web page address

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Ahvaz University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Ahvaz University of Medical Sciences

Full name of responsible person

Narges Sadeghi

Position

Msc Student

Latest degree

Master

Other areas of specialty/work

Nutrition

Street address

Faculty of Paramedicine, Jundishapur University of Medical Sciences

City

Ahvaz

Province

Khouzestan

Postal code

6135815751

Phone

+98 61 3321 4578

Fax

Email

sadeghi.n@ajums.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity

Ahvaz University of Medical Sciences

Full name of responsible person

Anahita Mansoori

Position

Assistant Professor

Latest degree

Ph.D.

Other areas of specialty/work

Nutrition

Street address

Paramedical School, Ahvaz Jundishapur University of Medical Sciences, Golestan Blvd, Ahvaz

City

Ahvaz

Province

Khouzestan

Postal code

61357-15794

Phone

+98 61 3336 7543

Email

mansoori_anahita@yahoo.com

Person responsible for updating data

Contact

Name of organization / entity

Ahvaz University of Medical Sciences

Full name of responsible person

Narges Sadeghi

Position

Msc Student

Latest degree

Master

Other areas of specialty/work

Nutrition

Street address

Faculty of Paramedicine, Jundishapur University of Medical Sciences

City

Ahvaz

Province

Khouzestan

Postal code

6135815751

Phone

+98 61 3321 4578

Fax

Email

sadeghi.n@ajums.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available

Title and more details about the data/document

If the decision is to publish the data, after the unidentified individuals all data will be published.

When the data will become available and for how long

The access period will be 6 months after the publication of the results.

To whom data/document is available

Researchers working in academic and industrial institutions can apply to get data.

Under which criteria data/document could be used

To cite. Referring to reference or researcher's permission

From where data/document is obtainable

Narges Sadeghi Faculty of Paramedicine, Jundishapur
University of Medical Sciences, Golestan Blvd, Ahvaz.
06133214578 sadeghi.n@ajums.ac.ir

What processes are involved for a request to access**data/document**

Access to articles related to this research Send email to
the responsible author

Comments